



#211 Sub 36
2/19/02
Docket No. APBI-P16-316

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

Belshaw, et al.	Art Unit:	1636
Serial No: 09/466,568	Attorney Docket No.	APBI-P16-316
Filed: December 17, 1999	Examiner:	B. Loeb
For: Regulated Gene Therapy Using Specific Response Elements		

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on January 14, 2002
Date


Dawn Harmon

TECH CENTER 1600/2900

FEB 19 2002

RECEIVED

TRANSMITTAL OF SEQUENCE LISTING IN COMPUTER READABLE FORM
IN COMPLIANCE WITH 37 C.F.R. §§1.821(c), (e) AND 1.825(a), (b)

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is submitted in response to the Office Action mailed from the Patent Office on December 14, 2001, a copy is attached.

In accordance with 37 C.F.R. §1.821(e), the content of the sequence listing in the above-referenced patent application is identical to the sequence listing filed in the parent application, U.S. Serial No. 09/157,753, filed September 16, 1998. Application respectfully request that a copy of the sequence listing filed in the parent application be included in the above-identified application in lieu of the new CRF.

Additionally, Applicant maintains that the cancellation of and amendments to the pending claims in the response filed November 26, 2001 were responsive to each of

the art rejections. Accordingly compliance with the sequence requirements renders the response filed November 26, 2001 fully responsive.

Respectfully submitted,

ROPES AND GRAY

By 

David P. Halstead

Reg. No. 44,735

Telephone (617) 951-7000

Facsimile (617) 951-7050

Customer ID 28120